ISA Pharmaceuticals closes EUR26m funding round
ISA Pharmaceuticals, a clinical-stage immunotherapy company, has closed a EUR26 million funding round with participation from new investors including Invest-NL and existing investors including Regeneron. The proceeds of this round will be used to advance the lead product ISA101b towards first marketing authorisation as well as to broaden the clinical